The top executive at McKinsey & Company appeared before Congress to answer for the consulting firm’s role in fanning the opioid crisis and came under intense criticism from lawmakers. One likened the firm’s earnings from advising Purdue Pharma and other pharmaceutical companies to “blood money” from drug traffickers. Yet, pharma continues to be aligned with MBA spreadsheet consulting.
MCKINSEY
KEY TAKEAWAY: Rethinking pharma productivity, an article by McKinsey consulting, is full of corporate consulting gibberish and is proof that they really don’t understand the business of our industry is helping people and helping employees help patients.
Successful pharma companies will rethink their business and operating models, transform their cultures and capabilities, and adopt a new, longer-term mind-set that fosters innovation and bold strategic moves. These conclusions stem from three important themes.